Pancreatic cancer surgery — experience of one medical center

Abstract

BACKGROUND: This article offers detailed information about the surgical treatment of pancreatic cancer, based on the experience of the abdominal department of Samara Regional Clinical Oncological Dispensary (Samara, Russian Federation). This allows readers to familiarize themselves with the achievements and innovations in this field, to get information about constantly improving surgical methods and their effectiveness. Such information can help not only patients, but also medical professionals, including surgeons, to improve the quality and effectiveness of operations. The article also includes an overview of the main methods of diagnosing pancreatic cancer, which can help specialists identify the disease at an early stage and improve their working methods. It provides up-to-date information on the diagnosis, treatment and prognosis of pancreatic cancer, which can help improve treatment outcomes and prolong the survival of patients suffering from this disease.

AIM: Analysis of the state of oncological care for patients with pancreatic cancer in the Samara region over the past 5 years.

METHODS: The results of treatment of 236 patients with pancreatic cancer operated in the department of abdominal oncology of the Samara Regional Clinical Oncology Dispensary in the period from 2018 were studied.

RESULTS: According to the results of treatment, pancreatic cancer stage IA was established in 9.74% of patients (n=23), stage IV — in 5.89% (n=14), stage IIA — 12.71% (n=30), stage IIB — in 12.71% (n=30); stage III — in 23.30% (n=55), stage IV — in 35.59% (n=84) of patients. Of the 76 patients with initially unresectable tumors, 12 received neoadjuvant chemotherapy according to the FOLFIRINOX scheme, which allowed them to perform radical surgery. The average age of the patients was 62.2 years. The overall survival rate in the entire group of patients was 20 months. It is interesting to note that in the group of patients with stage III, the 1-year survival rate was 20.53%, which is lower than in the group of patients with stage IV (25.59%). Most likely, this is due to postoperative complications and mortality in patients with stage III who underwent radical treatment (while patients with stage IV underwent gentle palliative surgery).

CONCLUSIONS: Pancreatic cancer is a complex disease that requires an interdisciplinary approach to achieve the necessary diagnosis and develop optimal treatment tactics. Radical surgery is disabling, but remains the only treatment option for pancreatic cancer, which determines the patient’s life prognosis. The results of gastropancreatoduodenal resection are characterized by a significant frequency of postoperative complications (34.38%), with a high rate of postoperative mortality (20.93%). Unsatisfactory results of surgical treatment of pancreatic cancer indicate the need to develop more effective methods of complex treatment. The lack of verification of pancreatic cancer at the prehospital stage in the majority of patients (84.6%) does not allow chemotherapy treatment in the neoadjuvant mode for locally advanced forms, which dooms patients to diagnostic surgery. As a result, valuable time is lost, which calls into question the well-being of such patients. The development of new, more effective diagnostic methods at the outpatient stage will solve this problem.

Keywords

pancreatic cancer / gastropancreatoduodenal resection / distal pancreatic resection with splenectomy / neoadjuvant chemotherapy

References

[1] Pancreatic cancer. Clinical Guidelines. ID 355. Approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation. 2020. Available from: https://cr.minzdrav.gov.ru/recomend/355_4 (In Russ)

[2] Клинические рекомендации — Рак поджелудочной железы. ID 355. Одобрено Научно-практическим Советом Минздрава РФ. 2020. Режим доступа: https://cr.minzdrav.gov.ru/recomend/355_4 Дата обращения: 04.06.2021

[3] Rasulov RI, Shelekhov AV, Man’kova TL, Neustroev VG. Extended gastropancreatoduodenectomy: detailed clinical and pathology analyses. Vestnik RONTs im. N.N. Blokhina RAMN. 2008;19(1):64–70. (In Russ).

[4] Расулов Р.И., Шелехов А.В., Манькова Т.Л., Неустроев В.Г. Расширенная гастропанкреатодуоденальная резекция: углубленный клинический и патологоанатомический анализ // Вестник РОНЦ им. Н.Н. Блохина РАМН. 2008. Т. 19, № 1. С. 64–70.

[5] Kaprin AD, Starinskii VV, Shakhzadova AO, editors. Moscow: MNIOI im. P.A. Gertsena − NMRRC of the Ministry of Health of Russia branch; 2022. (In Russ).

[6] Состояние онкологической помощи населению России в 2021 году / под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. Москва : МНИОИ им. П.А. Герцена — филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022.

[7] Katz MHG, Marsh R, Herman JM, et al. Borderline resectable pancreatic cancer: Need for standardization and methods for optimal clinical trial design. Annals of surgical oncology. 2013;20(8):2787–2795. doi: 10.1245/s10434-013-2886-9

[8] Katz M.H.G., Marsh R., Herman J.M., et al. Borderline resectable pancreatic cancer: Need for standardization and methods for optimal clinical trial design // Annals of surgical oncology. 2013. Vol. 20, N 8. P. 2787–2795. doi: 10.1245/s10434-013-2886-9

[9] Egorova AG, Orlov AE, Somov AN, et al. Malignant neoplasms in the Samara region in 2020–2021: a review of statistical information based on the results of processing the databases of the Samara Cancer Registry as of October 31, 2022. Indicators of morbidity, mortality, survival and health care status. Saratov: Amirit LLC, 2022.

[10] Егорова А.Г., Орлов А.Е., Сомов А.Н., и др. Злокачественные новообразования в Самарской области в 2020-2021 годы: обзор статистической информации по результатам обработки базы данных Самарского ракового регистра по состоянию на 31.10.2022 г. Показатели заболеваемости, смертности, выживаемости и состояния медицинской помощи. Саратов : ООО «Амирит», 2022.

[11] Kostina YuD, Pavelets KV. Diagnosis and treatment of pancreatic cancer the current state of the problem. Medicine: Theory and Practice. 2018;3(3):16–26. (In Russ).

[12] Костина Ю.Д., Павелец К.В. Диагностика и лечение рака поджелудочной железы современное состояние проблемы // Медицина: теория и практика. 2018. Т. 3, № 3. С. 16–26.

[13] Kuchin DM. Selection of the optimal method of pancreatodigestive anastomosis formation at gastropancreaticoduodenal resection: Cand. Sci. (Med.) dissertation. Moscow; 2017. (In Russ).

[14] Кучин Д.М. Выбор оптимального способа формирования панкреатодигестивного анастомоза при гастропанкреатодуоденальной резекции : дис. канд. мед. наук. Москва, 2017.

Funding

Государственное бюджетное учреждение здравоохранения «Самарский областной клинический онкологический диспансер»Samara regional clinical Oncology dispensary

RIGHTS & PERMISSIONS

Eco-Vector